Crown, Bijan J
Your individual circumstances determine value
Nausea, constipation, and reflux are common, especially during dose escalation, and going slower or staying lower feels like the obvious fix
Clinical decisions should be individualized based on patient preferences, comorbidities, medication regimens, and treatment goals, with ongoing medical supervision to monitor safety and efficacy
172 GSBR-1290 GSBR-1290 is an oral small molecule GLP-1RA developed by Structure Therapeutics, aimed at treating T2DM and obesity
GLP-1 medications can be used with SGLT2 inhibitors (medicines that help the kidneys remove sugar from the blood), but monitoring for dehydration and other side effects is needed